Drugs & Targets ClonoSEQ assay receives expanded FDA clearance to assess MRD in CLL September 04, 2020Vol.46 No.33
Drugs & Targets Melflufen receives FDA Priority Review for triple-class refractory multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets FDA to evaluate cancer therapies in patients with brain metastases September 04, 2020Vol.46 No.33
Drugs & Targets FDA updates analysis of medical device reports of breast implant illness and breast implant-associated lymphoma September 04, 2020Vol.46 No.33
Drugs & Targets Dragonfly Therapeutics, BMS agree to exclusive global license for IL-12 investigational immunotherapy program September 04, 2020Vol.46 No.33
Drugs & Targets Thermo Fisher Scientific, Hengrui Therapeutics to develop companion diagnostic in NSCLC indication September 04, 2020Vol.46 No.33
Drugs & TargetsFree Tecentriq approved by FDA for BRAF V600 unresectable or metastatic melanoma July 31, 2020Vol.46 No.31
Drugs & TargetsFree FDA approves first cell-based gene therapy for adult patients with relapsed or refractory MCL July 31, 2020Vol.46 No.31
Drugs & TargetsFree Keytruda receives two sBLA acceptances from FDA in TNBC in indications July 31, 2020Vol.46 No.31
Drugs & TargetsFree HIF-2α inhibitor MK-6482 receives FDA Breakthrough Designation for Von Hippel-Lindau Disease-associated RCC July 31, 2020Vol.46 No.31
